Intellia CEO granted options and RSUs

LEONARD JOHN M reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

LEONARD JOHN M reported acquisition or exercise transactions in this Form 4 filing.

Intellia Therapeutics, Inc. President and CEO John M. Leonard reported equity awards and updated his holdings. He received a stock option for 225,400 shares of common stock, granted at a price of $0.00 per share. He was also granted 156,400 shares of common stock in the form of restricted stock units, each representing a contingent right to receive one share of Intellia common stock. The option was granted on March 1, 2026, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter. After these awards, he directly owned 1,169,739 shares of common stock and indirectly held 58,415 shares through the John M. Leonard 2015 Irrevocable Trust.

Insider Trade Summary

Grant/Award: 381,800 shares

Grant/Award 3 txns

Insider LEONARD JOHN M

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	225,400	$0.00	$0.00
Grant/Award	Common Stock	156,400	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (right to buy) — 225,400 contracts (Direct); Common Stock — 1,169,739 shares (Direct); Common Stock — 58,415 shares (Indirect, By Trust)

Footnotes (3)

1. F1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
2. F2. Shares held by the John M. Leonard 2015 Irrevocable Trust.
3. F3. This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did NTLA CEO John M. Leonard report?

John M. Leonard reported receiving a stock option for 225,400 shares and 156,400 restricted stock units of Intellia common stock. Both awards were granted on March 1, 2026 and reflect equity compensation, not open-market buying or selling of existing shares.

How many Intellia (NTLA) stock options were granted to John M. Leonard?

He was granted a stock option covering 225,400 shares of Intellia common stock at a price of $0.00 per share. This option vests 33% on January 1, 2027, with the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

What restricted stock unit grant did Intellia’s CEO receive in this Form 4?

He received 156,400 shares of Intellia common stock in the form of restricted stock units. Each unit represents a contingent right to receive one share of common stock, providing additional equity-based compensation tied directly to Intellia’s shares.

What is the vesting schedule for John M. Leonard’s new Intellia stock option?

The stock option granted March 1, 2026 vests 33% on January 1, 2027. The remaining 67% vests in 24 substantially equal monthly installments afterward, creating a multi‑year vesting period tied to his continued service and performance.

How many Intellia (NTLA) shares does John M. Leonard own after these transactions?

Following the reported equity awards, he directly owned 1,169,739 shares of Intellia common stock. In addition, 58,415 shares were held indirectly by the John M. Leonard 2015 Irrevocable Trust, reflecting his overall reported share exposure.

How are trust-held Intellia shares reported for John M. Leonard?

The filing shows 58,415 shares of Intellia common stock held indirectly by the John M. Leonard 2015 Irrevocable Trust. These are reported as indirect ownership, distinct from his directly held shares, and are specifically identified as held by that trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 04:19 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LEONARD JOHN M

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

40 ERIE STREET; SUITE 130

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	03/01/2026		A		156,400	A	$0	1,169,739	D
Common Stock								58,415	I	By Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$13.78	03/01/2026		A		225,400		(3)	02/29/2036	Common Stock	225,400	$0	225,400	D

Explanation of Responses:

1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

2. Shares held by the John M. Leonard 2015 Irrevocable Trust.

3. This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

	James Basta, attorney-in-fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.